Home › Funds › MPM BioImpact LLC › EWTX
MPM BioImpact LLC position in EWTX
EDGEWISE THERAPEUTICS INC · Health Care
MPM BioImpact LLC reported holding 1,620,780 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$65.9M, representing 4.02% of its reported portfolio and ranking #6 among its reported holdings. MPM BioImpact LLC has disclosed EWTX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's EWTX position evolved
MPM BioImpact LLC first disclosed a stake in EWTX in Q1 2024 at 441,259 shares (US$8.0M). The position peaked in Q2 2026 at 1,620,780 shares, worth US$65.9M. Across 10 filings, MPM BioImpact LLC increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,620,780 shares valued at US$65.9M — a reduction of -39,916 shares quarter over quarter.. Notable position changes include a 68% increase in Q2 2024 (shares rose 48% over the following quarter), a 56% increase in Q2 2025 (shares rose 24% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 441.26K | $8.05M | New |
| Q2 2024 | 740.66K | $13.34M | Add |
| Q3 2024 | 917.17K | $24.48M | Add |
| Q4 2024 | 1.08M | $28.82M | Add |
| Q1 2025 | 1.11M | $24.32M | Add |
| Q2 2025 | 1.72M | $22.56M | Add |
| Q3 2025 | 1.72M | $27.91M | Hold |
| Q4 2025 | 1.66M | $41.08M | Reduce |
| Q1 2026 | 1.66M | $52.31M | Hold |
| Q2 2026 | 1.62M | $65.85M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EWTX and 13F data
EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EWTX
- ORBIMED ADVISORS LLC 15.52M sh · $630.52M · Q2 2026
- Paradigm Biocapital Advisors LP 10.22M sh · $415.05M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 8.39M sh · $341.00M · Q2 2026
- Novo Holdings A/S 5.35M sh · $217.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.73M sh · $192.12M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.37M sh · $177.71M · Q2 2026
- BAKER BROS. ADVISORS LP 3.70M sh · $150.40M · Q2 2026
- Siren, L.L.C. 3.18M sh · $129.39M · Q2 2026
- Cormorant Asset Management, LP 2.51M sh · $101.98M · Q2 2026
- Integral Health Asset Management, LLC 2.00M sh · $81.26M · Q2 2026
- BRAIDWELL LP 2.00M sh · $81.14M · Q2 2026
- First Light Asset Management, LLC 1.10M sh · $44.50M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held EWTX?
MPM BioImpact LLC has disclosed EWTX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is MPM BioImpact LLC's current position in EWTX?
As of Q2 2026, MPM BioImpact LLC holds 1.62M shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $65.85M, representing 4.02% of its reported portfolio and ranking #6.
Has MPM BioImpact LLC been buying or selling EWTX?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in EWTX. The position peaked in Q2 2026 at 1.62M shares.
Which other funds hold EWTX?
Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.